MétaCan
Menu
Back to cohort
Record W4416140972 · doi:10.1093/neuonc/noaf201.0589

CTP-17. Clinical stability following tovorafenib treatment in relapsed/refractory pediatric low-grade glioma: updated results from the phase 2 FIREFLY-1 trial

2025· article· en· W4416140972 on OpenAlexaff
Cassie Kline, Darren Hargrave, Dong-Anh Khong-Quang, Daniel Landi, Sarah Leary, Jasper van der Lugt, Sabine Mueller, Karsten Nysom, Sébastien Perreault, Angela J. Waanders, Olaf Witt, David S. Ziegler, Peter Manley, Jingyang Zhang, Elly Barry, Lindsay Kilburn

Bibliographic record

VenueNeuro-Oncology · 2025
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicMelanoma and MAPK Pathways
Canadian institutionsUniversité de MontréalCentre Hospitalier Universitaire Sainte-Justine
Fundersnot available
KeywordsClinical trialRadiographyDrugRetrospective cohort studyPhases of clinical researchDrug holiday

Abstract

fetched live from OpenAlex

Abstract BACKGROUND Tovorafenib is a selective, CNS-penetrant, type II RAF inhibitor that is FDA approved for recurrent BRAF-altered pLGG based on results of the ongoing FIREFLY-1 (NCT04775485) phase 2 study. METHODS 77 patients enrolled in the registrational arm (Arm 1) of FIREFLY-1. After 26 or more cycles (28 days each), patients could stop tovorafenib (drug holiday) and reinitiate upon radiographic or clinical evidence of progressive disease (PD). RESULTS As of May 10, 2024 data cutoff, objective response rate (ORR; RAPNO) for arm 1 (n=77) was 53%; median duration of response (DOR) was 18 months (range 12.0-22.8). 44 patients completed a 26-cycle course; 33/44 (75%) patients opted to enter drug holiday per protocol, with median follow-up since last dose of 4.4 months (range 0.2-11.6). 15/33 (45%) did not have radiographic PD prior to treatment cessation; PD events occurred in 5/15 patients by 6 months post treatment cessation. A more recent data extract (May 21, 2025) showed 5 additional patients entered drug holiday (n=38); median follow-up since last dose was 15.6 months (range 1.4-24.0). 30/38 (79%) remained clinically stable irrespective of radiographic response, with 28 (74%) remaining without retreatment ≥12 months from last dose. 2 patients exited study early, 7.7 months and 3 months from last dose. 8/38 (21%) were retreated with tovorafenib and remained on retreatment at time of extract. No new toxicities were reported with retreatment. Updated data from a prespecified data cut with approximately 36-month follow-up will be presented, including DOR, time to next treatment with ≥12 months off tovorafenib, and activity of tovorafenib at retreatment. CONCLUSIONS Tovorafenib induces durable responses with evidence of clinical stability off treatment in patients with recurrent BRAF-altered pLGG. Progression can occur after cessation, but retreatment is feasible.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Non-randomized trial · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.012

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0020.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0000.001
Science and technology studies0.0000.000
Scholarly communication0.0010.001
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.042
GPT teacher head0.353
Teacher spread0.311 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNon-randomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueNeuro-OncologySame topicMelanoma and MAPK PathwaysFrench-language works237,207